Your browser doesn't support javascript.
loading
Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.
Harashima, Shin-Ichi; Inagaki, Nobuya; Kondo, Kazuoki; Maruyama, Nobuko; Otsuka, Makiko; Kawaguchi, Yutaka; Watanabe, Yumi.
Affiliation
  • Harashima SI; Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Inagaki N; Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Kondo K; Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
  • Maruyama N; Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
  • Otsuka M; Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
  • Kawaguchi Y; Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
  • Watanabe Y; Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
Diabetes Obes Metab ; 20(7): 1770-1775, 2018 07.
Article in En | MEDLINE | ID: mdl-29473709
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Incretins / Canagliflozin / Sodium-Glucose Transporter 2 Inhibitors Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2018 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Incretins / Canagliflozin / Sodium-Glucose Transporter 2 Inhibitors Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2018 Document type: Article Affiliation country: Country of publication: